Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients.
BACKGROUND
In Japan, intravenous nifekalant (NIF) was often used for direct current cardioversion-resistant ventricular fibrillation (VF), until the use of intravenous amiodarone (AMD) was approved in 2007. The defibrillatory efficacy of NIF and AMD has thus far not been compared for resuscitation.


RESULTS
Between August 2007 and April 2009, 403 consecutive out-of-hospital patients with cardiopulmonary arrest were transferred to the Emergency Medical Service of Tokai University. Of these, 30 patients with first defibrillation failure or VF recurrence were enrolled for this NIF/AMD study. The final defibrillation success (and hospital survival rate) was 67% (10/15) in the AMD and 47% (7/15) in the NIF group. The discharge survival rate was 53% (8/15) in the AMD and 21% (4/15) in the NIF group (P = 0.06). Notably, all 4 survivors in the NIF group could take up normal daily life again, whereas this was restricted to only 2 patients from the 11 survivors in the AMD group. The difference is probably partly attributable to longer time from AMD administration to defibrillation success compared with NIF. In the cases of defibrillation failure, VF continued in 4/8 by NIF, however, asystole or pulseless electrical activity occurred in 4/5 patients by AMD.


CONCLUSIONS
AMD may be borderline superior over NIF to facilitate defibrillation in out-of-hospital patients with cardiopulmonary arrest. However, from the view point of preservation of brain function, NIF is not inferior to AMD for CPR.
Department of Cardiology, Tokai University School of Medicine, Isehara, Japan. mariam@is.icc.u-tokai.ac.jp
Mari
M
Amino
Koichiro
K
Yoshioka
Tobias
T
Opthof
Seiji
S
Morita
Shunryo
S
Uemura
Kozo
K
Tamura
Tomokazu
T
Fukushima
Shigeo
S
Higami
Hiroyuki
H
Otsuka
Kazuki
K
Akieda
Makiyoshi
M
Shima
Daisuke
D
Fujibayashi
Tadashi
T
Hashida
Sadaki
S
Inokuchi
Itsuo
I
Kodama
Teruhisa
T
Tanabe
D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004554:Electric Countershock; D004636:Emergency Service, Hospital; D005260:Female; D006323:Heart Arrest / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy
D000889:Anti-Arrhythmia Agents; D011744:Pyrimidinones; C076259:nifekalant; D000638:Amiodarone